Highlights include:
• Increased novel agent access in NZ improved MM survival
• Pomalidomide-based regimens for relapsed/refractory MM
• Daratumumab, lenalidomide + dexamethasone for untreated myeloma
Download here: Multiple Myeloma Research Review Issue 31